drugset / Trial / NCT00099164

Trial of Progesterone in Twins and Triplets to Prevent Preterm Birth (STTARS)

NCT00099164 ↗

RandomizedParallel-groupTriple-blindPrevention

Summary

Women pregnant with twins or triplets are at high risk of preterm birth, yet no intervention or approach has served to reduce this risk. A recently completed trial by the NICHD sponsored Maternal Fetal Medicine Units (MFMU) Network has, for the first time, demonstrated a treatment that substantially reduces the rate of preterm birth in women at high risk for preterm delivery (i.e. progesterone therapy). Preterm birth was reduced by 35% among progesterone-treated women with a singleton pregnancy when compared with women receiving placebo. The current trial compares weekly treatment by injection of progesterone with placebo in women pregnant with twins or triplets.

Timeline

Start
2004-04
Primary completion
2006-08
Completion
2007-09

Outcome

Missed primary endpoint

paper Treatment with 17 alpha-hydroxyprogesterone caproate did not reduce the rate of preterm birth in women with twin gestations. PMID 17671253 ↗

paper Treatment with 17 alpha-hydroxyprogesterone caproate did not reduce the rate of preterm birth in women with triplet gestations. PMID 19155896 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject 17-alpha-hydroxyprogesterone caproate Unknown 250 mg Intramuscular